For the quarter ending 2025-12-31, UPXI had -$620,458 decrease in cash & cash equivalents over the period. -$2,699,117 in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Unrealized (gain) on digital assets | - | 77,996,124 | 101,332 |
| Digital asset revenue | - | 6,083,617 | 985,009 |
| Loss on impairment of building | - | - | 0 |
| Impairment of goodwill and intangible assets | - | - | 0 |
| Net loss from operations | -178,924,930 | 66,748,122 | -13,684,209 |
| Depreciation and amortization | 153,578 | 155,092 | 757,758 |
| Unrealized loss on digital assets | -86,498,895 | - | - |
| Digital asset revenue | 11,227,130 | - | - |
| Gain on the sale of vitamedica and income from discontinued operations | - | - | 0 |
| Digital asset revenue conversion to usd | 4,771,563 | - | - |
| Loss on the sale of new england technology | - | - | 0 |
| Loss on digital asset revenue conversion to usd | 341,599 | - | - |
| Amortization of loan costs | 0 | 0 | 30,462 |
| Amortization of consideration discount | - | - | 0 |
| Inventory write-offs | - | - | 748,874 |
| Loss on sale of assets related to relocation of facility | - | - | 0 |
| Gain on sale of interactive offers | - | - | 0 |
| Loss on the disposal of assets | - | - | -10,743 |
| Bad debt reserve for amazon receivable | - | 229 | 933,950 |
| Reduction of acquisition payable | - | - | 152,500 |
| Issuance of stock for services | - | - | 250,000 |
| Lease impairment (gain on settlement) | - | - | 269,994 |
| Impairment on assets from manufacturing shut down | 1,422,289 | - | - |
| Change in deferred tax asset | - | - | 0 |
| Amortization of deferred financing costs | 953,618 | 794,681 | - |
| Stock-based compensation | 8,300,673 | 5,756,398 | 2,106,862 |
| Accounts receivable | 310,062 | 126,975 | 484,580 |
| Inventory | -307,407 | -117,190 | 470,188 |
| Prepaid expenses and other assets | -306,582 | 1,381,321 | -222,005 |
| Operating lease assets and liabilities, net | 9,045 | -7,079 | 20,965 |
| Accounts payable and accrued liabilities | 639,755 | 2,204,991 | 2,865,251 |
| Deferred revenue | -4,060 | 38,192 | -222,100 |
| Net cash provided by operating activities - continuing operations | - | - | -8,423,042 |
| Net cash provided by (used in) operating activities - discontinued operations | - | - | 0 |
| Net cash used in operating activities | -2,681,666 | -9,780,221 | -8,423,042 |
| Proceeds from the sale of building | 0 | 0 | 4,005,516 |
| Proceeds from the sale of vitamedica, inc | - | - | 0 |
| Proceeds from the sale of e-core | 0 | 0 | 2,000,000 |
| Proceeds from the sale of interactive offers, net of liabilities paid | - | - | 0 |
| Proceeds from the sale of mw products assets | 175,000 | - | - |
| Acquisition of digital assets | 36,225,236 | 29,579,741 | 104,910,839 |
| Acquisition of cygnet online llc, net | - | - | 0 |
| Investment in digital assets company | - | 750,000 | - |
| Acquisition of royalty interest | 750,000 | - | - |
| Acquisition of property and equipment | 17,451 | 14,827 | 387,760 |
| Net cash provided by (used in) investing activities - continuing operations | - | - | -99,293,083 |
| Net cash (used in) investing activities - discontinued operations | - | - | 0 |
| Net cash (used in) provided by investing activities | -6,487,946 | -30,344,568 | -99,293,083 |
| Payment of equity issuance costs | - | 2,992,085 | - |
| Proceeds from issuance of common stock | 10,000,000 | 50,000,000 | 92,556,053 |
| Payment on convertible note | - | - | 150,000 |
| Payments of equity issuance costs | 3,743,654 | - | - |
| Proceeds from issuance of short-term debt | - | - | 20,000,000 |
| Repurchases of common stock | 799,277 | - | - |
| Proceeds from exercise of pre-funded warrants | 0 | 7,889 | 250,000 |
| Issuance of preferred stock series a | - | - | 325,000 |
| Proceeds from exercise of warrants | 100,000 | - | - |
| Repayment of related party advance | 0 | 0 | 175,000 |
| Proceeds from related party advance | - | - | 75,000 |
| Proceeds from issuance of convertible notes | - | - | 350,000 |
| Repayment of related party note payable | - | - | 500,000 |
| Repayment on note payable on building | - | - | 2,634,538 |
| Net cash used in financing activities - continuing operations | - | - | 110,029,860 |
| Payments of debt issuance costs | 0 | 7,628,942 | - |
| Net cash (used in) provided by financing activities - discontinued operations | - | - | 0 |
| Repayment on note payable on building | 0 | 0 | -66,655 |
| Net cash provided by (used in) financing activities | 8,549,154 | 39,386,862 | 110,029,860 |
| Net decrease in cash | -620,458 | -737,927 | 2,313,735 |
| Effect of exchange rate changes on cash | - | - | 0 |
| Cash and cash equivalents at beginning of period | 2,237,223 | 2,975,150 | 661,415 |
| Cash and cash equivalents at end of period | 1,616,765 | 2,237,223 | 2,975,150 |
UPEXI, INC. (UPXI)
UPEXI, INC. (UPXI)